HSP90AA1, one of the HSP90 isoforms, showed a significant correlation with survival time in lung cancer patients by inhibiting the AKT1 and ERK pathways (Niu et al., 2021) and was upregulated in colorectal cancer (Szczuka et al., 2021). Here, HSP90AA1 is linked to lung carcinoma.